Quick Answer
EXOZYMES INC. reported Net Income Loss of -$9.16 million for the year ending 2025.
- EXOZYMES INC. showed a decrease of -56.3% in Net Income Loss from 2024 to 2025.
- This data is from EXOZYMES INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$241.2 thousand | Q2 2023: -$178.1 thousand | Q3 2023: -$520.6 thousand | Q1 2024: -$1.01 million | Q2 2024: -$1.36 million | Q3 2024: -$1.66 million | Q1 2025: -$1.86 million | Q2 2025: -$2.36 million | Q3 2025: -$2.29 million.
- Over the full 3 years of available data (2023 to 2025), EXOZYMES INC.'s Net Income Loss has declined by 349.3%.
- Historical annual values: Fiscal year 2025: -$9.16 million | Fiscal year 2024: -$5.86 million | Fiscal year 2023: -$2.04 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: